Physician profile
Brian A Williams
NPI 1528086873
$5,278.89
in general payments reported to CMS, 2019-2025
48 companies · $637 in 2025
The $637 reported for 2025 was more than what 79% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,399 · 2020: $1,639 · 2021: $849 · 2023: $134 · 2024: $621 · 2025: $637.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,392.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,391.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Monteris Medical Corporation | $1,167.20 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $349.84 | 2019-2025 | Tagrisso |
| Amgen INC. | $347.30 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $327.21 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Puma Biotechnology, INC. | $312.47 | 2019-2025 | |
| Elekta, INC. | $253.82 | 2020-2023 | Elekta Unity |
| Regeneron Healthcare Solutions, INC. | $227.06 | 2019-2025 | Libtayo |
| Novartis Pharmaceuticals Corporation | $197.59 | 2019-2025 | |
| Janssen Biotech, INC. | $142.53 | 2019-2025 | Erleada, Tecvayli |
| Telix Pharmaceuticals | $120.35 | 2024 | Illuccix |
| Lilly USA, LLC | $112.42 | 2020-2025 | Verzenio, Jaypirca, Retevmo |
| E.R. Squibb & Sons, L.L.C. | $112.03 | 2019-2025 | Opdivo |
| Bayer Healthcare Pharmaceuticals INC. | $97.90 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $95.01 | 2019-2025 | Vpriv, Iclusig |
| Kyowa Kirin, INC. | $92.68 | 2019-2021 |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.